Cynata Announces First Clinical Study Utilizing MSCs Manufactured by Cymerus™ Platform
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news today by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD.
The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study. [Read more…]